首页> 美国卫生研究院文献>Cancer Biology Therapy >SU11248 a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells
【2h】

SU11248 a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells

机译:SU11248一种选择性酪氨酸激酶抑制剂通过靶向肿瘤脉管系统和乳腺癌细胞抑制乳腺肿瘤血管生成和生长

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

SU11248 is a selective inhibitor of certain protein kinases including VEGFR types 1–3 that are expressed in human breast cancer. The present study determines whether the anti-tumor activity of SU11248 results from the inhibition of angiogenesis, as well as direct anti-proliferation and anti-migration effects on breast tumors. Eight-wk old female mice (C57BL/6) were given SU11248 at 20–40 mg/kg/d in drinking (distilled) water for 4 wks. Control mice received drinking water only. In the 2nd wk, 106 E0771 (mouse breast cancer) cells were injected in the left fourth mammary gland. Tumor size was monitored using dial calipers. At the end, tumors were isolated for measuring tumor size and intratumoral microvessel density (IMD) using CD31 immunohistochemistry. SU11248 significantly reduced tumor weight over the control (1.22 ± 0.28 vs. 3.28 ± 0.31 g; n = 8; p < 0.01) and IMD (111 ± 10 vs. 155 ± 6 IM#/mm2; p < 0.01). RT-PCR indicated that VEGFR1 and R2 were expressed in cultured E0771 cells. VEGF (10 ng/ml) caused a 42% increase in proliferation of E0771 cells, compared to the control (p < 0.01; n = 8), and there was a significant decrease in proliferation of E0771 cells treated with VEGF plus SU11248 (10 µmol/L) vs. the control (65%, p < 0.01). VEGF caused a 2-fold increase in the proliferation of HUVEC vs. the control (p < 0.01; n = 8), but its action was completely eradicated by SU11248. Neither VEGF nor SU11248 had any effect on the proliferation of cultured HAS MC. Migration assay showed that SU11248 (10 µmol/L) significantly inhibited the migration of cultured E0771 cells. SU11248 significantly inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a dose-related manner. These findings support the hypothesis that the anti-tumor activity of SU11248 on breast cancer is possibly mediated by targeting the paracrine and autocrine effects of VEGF on breast cancer to suppress tumor angiogenesis, proliferation and migration.
机译:SU11248是某些蛋白激酶的选择性抑制剂,包括在人乳腺癌中表达的1至3型VEGFR。本研究确定SU11248的抗肿瘤活性是否源于血管生成的抑制以及对乳腺肿瘤的直接抗增殖和抗迁移作用。八周龄雌性小鼠(C57BL / 6)在饮用水(蒸馏水)中以20-40 mg / kg / d的剂量服用SU11248,持续4周。对照小鼠仅接受饮用水。在第2周,将10 6 E0771(小鼠乳腺癌)细胞注射到左第四乳腺中。使用卡尺监测肿瘤大小。最后,使用CD31免疫组织化学分离肿瘤以测量肿瘤大小和肿瘤内微血管密度(IMD)。 SU11248与对照组相比(1.22±0.28 vs. 3.28±0.31 g; n = 8; p <0.01)和IMD(111±10 vs. 155±6 IM#/ mm 2 )显着降低了肿瘤重量; p <0.01)。 RT-PCR表明VEGFR1和R2在培养的E0771细胞中表达。与对照组相比,VEGF(10 ng / ml)导致E0771细胞的增殖增加42%(p <0.01; n = 8),并且用VEGF加SU11248处理的E0771细胞的增殖显着降低(10 µmol / L)与对照(65%,p <0.01)。相对于对照,VEGF导致HUVEC的增殖增加了2倍(p <0.01; n = 8),但SU11248完全消除了它的作用。 VEGF和SU11248均未对培养的HAS MC的增殖产生任何影响。迁移分析表明,SU11248(10 µmol / L)显着抑制了培养的E0771细胞的迁移。 SU11248以剂量相关的方式显着抑制MCF-7和MDA-MB-231细胞的增殖。这些发现支持以下假设:SU11248对乳腺癌的抗肿瘤活性可能是通过靶向VEGF对乳腺癌的旁分泌和自分泌作用来抑制肿瘤血管生成,增殖和迁移而介导的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号